• Improved management of cardiometabolic risk factors. Attainment of all lipid goals, including non-HDL cholesterol and apolipoprotein B, and desirable levels for HDL cholesterol and triglycerides, is essential.
  • Consistent evidence from two major prospective trials may merit consideration by clinicians of adjunctive fenofibrate therapy to slow progression of diabetic retinopathy in type 2 diabetes patients. These data provide a strong rationale for testing this in a major prospective study.
  • Table 4: Recommendations of the R3i to reduce the residual risk of diabetesrelated microvascular complications in patients with type 2 diabetes.